Compare PMT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | WVE |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 744.8M |
| IPO Year | 2009 | 2015 |
| Metric | PMT | WVE |
|---|---|---|
| Price | $7.38 | $3.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $11.11 | ★ $18.06 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 21.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $351,067,000.00 | $3,704,000.00 |
| Revenue This Year | N/A | $19.21 |
| Revenue Next Year | $12.07 | N/A |
| P/E Ratio | $18.73 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $7.31 | $3.37 |
| 52 Week High | $13.80 | $21.73 |
| Indicator | PMT | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 22.82 | 25.81 |
| Support Level | N/A | N/A |
| Resistance Level | $9.80 | $4.07 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 4.18 | 9.86 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.